The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abandoning the Notion of Non-Small Cell Lung Cancer
Abstract
Non-small cell lung cancers (NSCLCs) represent 85% of lung tumors. NSCLCs encompass multiple cancer types, such as adenocarcinomas (LUADs), squamous cell cancers (LUSCs), and large cell cancers. Among them, LUADs and LUSCs are the largest NSCLC subgroups. LUADs and LUSCs appear sharply distinct at the transcriptomic level, as well as for cellular control networks. LUADs show distinct genetic drivers and divergent prognostic profiles versus LUSCs. Therapeutic clinical trials in NSCLC indicate differential LUAD versus LUSC response to treatments. Hence, LUAD and LUSC appear to be vastly distinct diseases at the molecular, pathological, and clinical level. Abandoning the notion of NSCLC may critically help in developing novel, more effective subtype-specific molecular alteration-targeted therapeutic procedures.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713137 · Cited by 5,508
Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., & Johnson, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011954 · Cited by 4,955
The biology and management of non-small cell lung cancer
Herbst, R. S., Morgensztern, D., & Boshoff, C. (2018) · Nature · doi:10.1038/nature25183 · Cited by 4,891
The 2015 World Health Organization Classification of Lung Tumors
Travis, W. D., Brambilla, E., Nicholson, A. G., Yatabe, Y., Austin, J. H. M., Beasley, M. B., Chirieac, L. R., Dacic, S., Duhig, E., Flieder, D. B., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000630 · Cited by 4,520
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., Thomas, C. A., Barlesi, F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716948 · Cited by 3,733
COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER
Chiller, J. O. H. S., Arrington, D. A. H., Elani, C. H. P. B., Anger, C., Andler, A. L. S., Rook, J. A. K., Hu, J., & Ohnson, D. A. H. J. (2002) · Cited by 3,730
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Kurata, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809697 · Cited by 2,798
Tracking the Evolution of Non–Small-Cell Lung Cancer
Jamal-Hanjani, M., Wilson, G. A., McGranahan, N., Birkbak, N. J., Watkins, T. B. K., Veeriah, S., Shafi, S., Johnson, D. H., Mitter, R., Rosenthal, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1616288 · Cited by 2,349
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
Forde, P. M., Chaft, J. E., Smith, K. N., Anagnostou, V., Cottrell, T. R., Hellmann, M. D., Zahurak, M., Yang, S. C., Jones, D. R., Broderick, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716078 · Cited by 2,099
Masters, G. A., Temin, S., Azzoli, C. G., Giaccone, G., Baker, S., Brahmer, J. R., Ellis, P. M., Gajra, A., Rackear, N., Schiller, J. H., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.1342 · Cited by 850
Osmani, L., Askin, F., Gabrielson, E., & Li, Q. K. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.11.019 · Cited by 773
Gene Expression-Based Classification of Non-Small Cell Lung Carcinomas and Survival Prediction
Hou, J., Aerts, J., den Hamer, B., van IJcken, W., den Bakker, M., Riegman, P., van der Leest, C., van der Spek, P., Foekens, J. A., Hoogsteden, H. C., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010312 · Cited by 755
SpiroMeta Consortium, McKay, J. D., Hung, R. J., Han, Y., Zong, X., Carreras-Torres, R., Christiani, D. C., Caporaso, N. E., Johansson, M., Xiao, X., et al. (2017) · Nature Genetics · doi:10.1038/ng.3892 · Cited by 720
Kalemkerian, G. P., Narula, N., Kennedy, E. B., Biermann, W. A., Donington, J., Leighl, N. B., Lew, M., Pantelas, J., Ramalingam, S. S., Reck, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.7293 · Cited by 492
Piotrowska, Z., Isozaki, H., Lennerz, J. K., Gainor, J. F., Lennes, I. T., Zhu, V. W., Marcoux, N., Banwait, M. K., Digumarthy, S. R., Su, W., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1022 · Cited by 442
Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas
Campbell, J. D., Yau, C., Bowlby, R., Liu, Y., Brennan, K., Fan, H., Taylor, A. M., Wang, C., Walter, V., Akbani, R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.063 · Cited by 342
Lung Cancer Epidemiology, Risk Factors, and Prevention
de Groot, P., & Munden, R. F. (2012) · Radiologic Clinics of North America · doi:10.1016/j.rcl.2012.06.006 · Cited by 332
Third generation EGFR TKIs: current data and future directions
Tan, C.-S., Kumarakulasinghe, N. B., Huang, Y.-Q., Ang, Y. L. E., Choo, J. R.-E., Goh, B.-C., & Soo, R. A. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0778-0 · Cited by 311
Deciphering the cells of origin of squamous cell carcinomas
Sánchez-Danés, A., & Blanpain, C. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0024-5 · Cited by 261
Scagliotti, G., Brodowicz, T., Shepherd, F. A., Zielinski, C., Vansteenkiste, J., Manegold, C., Simms, L., Fossella, F., Sugarman, K., & Belani, C. P. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181f7c6d4 · Cited by 252
Origins, genetic landscape, and emerging therapies of small cell lung cancer
Semenova, E. A., Nagel, R., & Berns, A. (2015) · Genes & Development · doi:10.1101/gad.263145.115 · Cited by 250
Trop-2 Is a Determinant of Breast Cancer Survival
Ambrogi, F., Fornili, M., Boracchi, P., Trerotola, M., Relli, V., Simeone, P., La Sorda, R., Lattanzio, R., Querzoli, P., Pedriali, M., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096993 · Cited by 221
Self-citationLung cancer in never smokers: Disease characteristics and risk factors
Pallis, A. G., & Syrigos, K. N. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.06.011 · Cited by 185
An Expression Signature as an Aid to the Histologic Classification of Non–Small Cell Lung Cancer
Girard, L., Rodriguez-Canales, J., Behrens, C., Thompson, D. M., Botros, I. W., Tang, H., Xie, Y., Rekhtman, N., Travis, W. D., Wistuba, I. I., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2900 · Cited by 154
Kadota, K., Nitadori, J., Woo, K. M., Sima, C. S., Finley, D. J., Rusch, V. W., Adusumilli, P. S., & Travis, W. D. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000253 · Cited by 133
Overall and Central Obesity and Risk of Lung Cancer: A Pooled Analysis
Yu, D., Zheng, W., Johansson, M., Lan, Q., Park, Y., White, E., Matthews, C. E., Sawada, N., Gao, Y.-T., Robien, K., et al. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djx286 · Cited by 131
Lai, G. G. Y., Lim, T. H., Lim, J., Liew, P. J. R., Kwang, X. L., Nahar, R., Aung, Z. W., Takano, A., Lee, Y. Y., Lau, D. P. X., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00177 · Cited by 118
LUBAC determines chemotherapy resistance in squamous cell lung cancer
Ruiz, E. J., Diefenbacher, M. E., Nelson, J. K., Sancho, R., Pucci, F., Chakraborty, A., Moreno, P., Annibaldi, A., Liccardi, G., Encheva, V., et al. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20180742 · Cited by 94
Trop-2 Induces Tumor Growth Through AKT and Determines Sensitivity to AKT Inhibitors
Guerra, E., Trerotola, M., Tripaldi, R., Aloisi, A. L., Simeone, P., Sacchetti, A., Relli, V., D’Amore, A., Sorda, R. L., Lattanzio, R., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1701 · Cited by 65
Self-citationDNA methylation prevents the amplification of TROP1, a tumor-associated cell surface antigen gene.
Alberti, S., Nutini, M., & Herzenberg, L. A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.13.5833 · Cited by 49
Self-citationPathway-based gene signatures predicting clinical outcome of lung adenocarcinoma
Chang, Y.-H., Chen, C., Chen, H., & Yang, P. (2015) · Scientific Reports · doi:10.1038/srep10979 · Cited by 47
Osimertinib (AZD9291) increases radio‑sensitivity in EGFR T790M non‑small cell lung cancer
Wang, N., Wang, L., Meng, X., Wang, J., Zhu, L., Liu, C., Li, S., Li, Z., Yang, Z., Xing, L., et al. (2018) · Oncology Reports · doi:10.3892/or.2018.6803 · Cited by 45
Ricciuti, B., Baglivo, S., Paglialunga, L., Giglio, A. D., Bellezza, G., Chiari, R., Crinò, L., & Metro, G. (2017) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017702820 · Cited by 41
Distinct lung cancer subtypes associate to distinct drivers of tumor progression
Relli, V., Trerotola, M., Guerra, E., & Alberti, S. (2018) · Oncotarget · doi:10.18632/oncotarget.26217 · Cited by 40
Self-citationMolecular signature and pathway analysis of human primary squamous and adenocarcinoma lung cancers.
Daraselia, N., Wang, Y., Budoff, A., Lituev, A., Potapova, O., Vansant, G., Monforte, J., Mazo, I. A., & Ossovskaya, V. (2012) · Europe PMC (PubMed Central) · Cited by 38
Liu, J., Yang, X., & Shi, W. (2014) · Genetics and Molecular Research · doi:10.4238/2014.january.8.8 · Cited by 38
Mutations of TP53 induce loss of DNA methylation and amplification of the TROP1 gene
Nasr, A. F., Nutini, M., Palombo, B., Guerra, E., & Alberti, S. (2003) · Oncogene · doi:10.1038/sj.onc.1206248 · Cited by 35
Self-citationp53, cathepsin D, Bcl-2 are joint prognostic indicators of breast cancer metastatic spreading
Guerra, E., Cimadamore, A., Simeone, P., Vacca, G., Lattanzio, R., Botti, G., Gatta, V., D’Aurora, M., Simionati, B., Piantelli, M., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2713-3 · Cited by 30
Self-citationTargeted Molecular Treatments in Non-Small Cell Lung Cancer: A Clinical Guide for Oncologists
Bui, K. T., Cooper, W. A., Kao, S., & Boyer, M. J. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7080192 · Cited by 29
Gene Expression Signature Differentiates Histology But Not Progression Status of Early-Stage NSCLC
Charkiewicz, R., Nikliński, J., Claesen, J., Sulewska, A., Kozłowski, M., Michalska‐Falkowska, A., Reszeć, J., Moniuszko, M., Naumnik, W., & Niklińska, W. (2017) · Translational Oncology · doi:10.1016/j.tranon.2017.01.015 · Cited by 28
Camidge, D. R., & Davies, K. D. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00033 · Cited by 27
Rybarczyk-Kasiuchnicz, A., & Ramlau, R. (2018) · Polish Journal of Cardio-Thoracic Surgery · doi:10.5114/kitp.2018.76478 · Cited by 14
Chen, R., Ding, Z., Zhu, L., et al. (2017) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2017.09.011 · Cited by 12
Osimertinib in first-line treatment—is a comparison not proof?
Cadranel, J. L. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2017.12.13 · Cited by 3
West, H. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.08.29 · Cited by 2
Cited by
Imyanitov, E. N., Iyevleva, A. G., & Levchenko, E. V. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103194 · Cited by 526
Targeted Therapy and Checkpoint Immunotherapy in Lung Cancer
Ruiz-Cordero, R., & Devine, W. P. (2020) · Surgical Pathology Clinics · doi:10.1016/j.path.2019.11.002 · Cited by 448
Machine Learning for Lung Cancer Diagnosis, Treatment, and Prognosis
Li, Y., Wu, X., Yang, P., Jiang, G., & Luo, Y. (2022) · Genomics, Proteomics & Bioinformatics · doi:10.1016/j.gpb.2022.11.003 · Cited by 263
Tumor metabolic reprogramming in lung cancer progression (Review)
Li, X., Liu, M., Liu, H., & Chen, J. (2022) · Oncology Letters · doi:10.3892/ol.2022.13407 · Cited by 52
Interpretable meta-learning of multi-omics data for survival analysis and pathway enrichment
Cho, H. J., Shu, M., Bekiranov, S., Zang, C., & Zhang, A. (2023) · Bioinformatics · doi:10.1093/bioinformatics/btad113 · Cited by 42
Metadata
- Authors
- Relli, V., Trerotola, M., Guerra, E., & Alberti, S.
- Venue
- Trends in Molecular Medicine
- Publisher
- Elsevier BV
- Published
- 2019-07
- Volume
- 25
- Issue
- 7
- Pages
- 585-594
- ISSN
- 1471-4914 (ISSN-L)
- OpenAlex
- W2947780266
- Cited by
- 461
- References
- 45
- FWCI
- 3.95
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.